Algorithm for assessing the level of T cell immune response against SARS-CoV-2 and the results of its application in unvaccinated and vaccinated people who have been infected with COVID-19
- Authors: Blyakher M.S.1, Fedorova I.M.1, Koteleva S.I.1, Kapustin I.V.1, Tulskaya E.A.1, Ramazanova Z.K.1, Odintsov E.E.1, Sandalova S.V.1, Novikova L.I.1, Bochkareva S.S.1
-
Affiliations:
- G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
- Issue: Vol 14, No 3 (2024)
- Pages: 451-458
- Section: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/2220-7619/article/view/262063
- DOI: https://doi.org/10.15789/2220-7619-AFA-16736
- ID: 262063
Cite item
Full Text
Abstract
Antigen (AG)-specific T cell activity was compared in two groups of patients: those who underwent COVID-19 in 2021 during the circulation of the SARS-CoV-2 delta virus strain (43 individuals); and those who underwent COVID-19 in 2022 (Omicron strain, 23 individuals). The diagnosis was confirmed by PCR analysis of nasopharyngeal and oropharyngeal swabs. The 23 individuals following COVID-19 caused by SARS-CoV-2 (omicron) were part of a cohort of 41 volunteers who were examined multiple times during 2021–2023: during vaccination, after vaccination, before revaccination, and subsequently after illness (6–8 times in total). Due to this, it was possible to compare the indices of specific humoral and cellular immunity in the same patients 1–2 months before and after breakthrough infection. Detection of AG-specific T cells and assessment of their activity by AG-stimulated IFNγ production was carried out by our own previously developed method (Patent RU № 2780369 C1). For stimulation of memory T effectors in vitro, the same antigens were used to determine the concentration of antibodies against SARS-CoV-2 by ELISA method. A total of about 300 blood samples from healthy subjects and patients after COVID-19 were analyzed. Each sample was tested against 3 SARS-CoV-2 antigens and in 2 stimulation modes. A qualitative assessment algorithm for AG-specific T cell activity has been proposed that can be used to monitor the state of cellular immunity in a population in which SARS-CoV-2 virus continues to circulate and to create insights into what level of T cell activation is sufficient to prevent or reduce the severity of SARS-CoV-2 infection. Unvaccinated COVID-19 (SARS-CoV-2, Delta) survivors lacked AG-specific T cells to RBD SARS-CoV-2, but T cell specificity to full-length S glycoprotein at the same level, qualitatively assessed as low in 52% of the group, persisted for up to six months. In previously unvaccinated COVID-19 vaccinees, this duration of persistence of AG-specific T cells in circulating blood was achieved only after revaccination. Hybrid immunity, which we traced as a result of vaccination after COVID-19 (Delta strain) or as a breakthrough infection (SARS-CoV-2, Omicron), is characterized by the highest indices of memory T cell activity (43–46% of the group — normal activity of AG-specific cells, 30–43% — high activity) to all used antigens and the longest duration of preservation of indices at this level. Further investigation of the level of antiviral immunity after COVID-19 may be important for predicting the outcome of new waves of SARS-CoV-2 infection.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
M. S. Blyakher
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
DSc (Medicine), Professor, Head, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10Irina M. Fedorova
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Author for correspondence.
Email: vestnik-07@mail.ru
PhD (Medicine), Leading Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10S. I. Koteleva
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Medicine), Leading Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10I. V. Kapustin
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Medicine), Leading Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10E. A. Tulskaya
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Biology), Leading Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10Z. K. Ramazanova
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Medicine), Leading Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10
E. E. Odintsov
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Medicine), Senior Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10S. V. Sandalova
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
Research Associate, Laboratory for the Study of Cellular and Molecular Bases of Immunity
Russian Federation, 125212, Moscow, Admiral Makarov str., 10L. I. Novikova
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
PhD (Medicine), Head of the Laboratory of Immunobiological Preparations
Russian Federation, 125212, Moscow, Admiral Makarov str., 10S. S. Bochkareva
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
Email: vestnik-07@mail.ru
DSc (Biology), Leading Research Associate, Laboratory of Immunobiological Preparations
Russian Federation, 125212, Moscow, Admiral Makarov str., 10References
- Бляхер М.С., Федорова И.М., Тульская Е.А., Капустин И.В., Котелева С.И., Рамазанова З.К., Одинцов Е.Е., Сандалова С.В., Новикова Л.И. Определение специфического Т-клеточного иммунитета к антигенам вируса SARS-CoV-2 у людей, переболевших COVID-19 // Вопросы вирусологии, 2022. Т. 67, № 6. C. 527–537. [Blyakher M.S., Fedorova I.M., Tulskaya E.A., Kapustin I.V., Koteleva S.I., Ramazanova Z.K., Odintsov E.E., Sandalova S.V., Novikova L.I. Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. Voprosy Virusologii = Problems of Virology, 2022, vol. 67, no. 6, pp. 527–537. (In Russ.)]
- Бляхер М.С., Федорова И.М., Тульская Е.А., Капустин И.В., Котелева С.И., Рамазанова З.К., Одинцов Е.Е., Сандалова С.В., Новикова Л.И., Алешкин А.В., Бочкарева С.С. Формирование и сохранение специфического Т-клеточного иммунитета после перенесенной SARS-CoV-2 инфекции или вакцинации против нее // Вопросы вирусологии, 2023. Т. 68, № 3. C. 205–214. [Blyakher M.S., Fedorova I.M., Tulskaya E.A., Kapustin I.V., Koteleva S.I., Ramazanova Z.K., Odintsov E.E., Sandalova S.V., Novikova L.I., Aleshkin A.V., Bochkareva S.S. Development and preservation of specific T-cell immunity after a SARS-CoV-2 infection or vaccination against it. Voprosy Virusologii = Problems of Virology, 2023, vol. 68, no. 3, pp. 205–214. (In Russ.)]
- Патент № 2780369 Российская Федерация, МПК G01N 33/68 (2006.01), G01N 33/569 (2006.01), G01N 33/543 (2006.01), G01N 33/573 (2006.01), G01N 33/531 (2006.01), C12N 5/0786 (2010.01). Способ определения специфического клеточного иммунного ответа на антигены коронавируса (SARS-CoV-2): № 2021139712; заявлено 29.12.2021: опубликовано 21.09.2022 / Бляхер М.С., Капустин И.В., Одинцов Е.Е., Рамазанова З.К., Сандалова С.В., Тульская Е.А., Федорова И.М.; заявитель и патентообладатель ФБУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора. 16 с. [Patent No. 2780369 Russian Federation, Int. G01N 33/68 (2006.01), G01N 33/569 (2006.01), G01N 33/543 (2006.01), G01N 33/573 (2006.01), G01N 33/531 (2006.01), C12N 5/0786 (2010.01). Method for determining the specific cellular immune response to coronavirus antigens (SARS-CoV-2). No. 2021139712; application: 29.12.2021: date of publication 21.09.2022 / Blyaher M.S., Kapustin I.V., Odintsov E.E., Ramazanova Z.K., Sandalova S.V., Tul’skaya E.A., Fedorova I.M. Proprietors: Federalnoe Byudzhetnoe uchrezhdenie nauki “Moskovskij nauchno-issledovatelskij institut epidemiologii i mikrobiologii im. G.N. Gabrichevskogo” Federalnoj sluzhby po nadzoru v sfere zashchity prav potrebitelej I blagopoluchiya cheloveka. 16 p.]
- Топтыгина А.П., Афридонова З.Э., Закиров Р.Ш., Семикина Е.Л. Поддержание иммунологической памяти к вирусу SARS-CoV-2 в условиях пандемии // Инфекция и иммунитет, 2023. Т. 13, № 1. C. 55–66. [Toptygina A.P., Afridonova Z.E., ZakirovR.Sh., Semikina E.L. Maintaining immunological memory to the SARS-CoV-2 virus during COVID-19 pandemic. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2023, vol. 13, no. 1, pp. 55–66. (In Russ.)] doi: 10.15789/2220–7619-MIM-2009.
- Agallou M., Koutsoni O.S., Michail M., Zisimopoulou P., Tsitsilonis O.E., Karagouni E. Antibody and T-cell subsets analysis unveils an immune profile heterogeneity mediating longterm responses in individuals vaccinated against SARS-CoV-2. J. Inf. Dis., 2023, vol. 227, no. 3, pp. 353–363.
- Almendro-Vazquez P., Laguna-Goya R. Paz-Artal E. Defending against SARS-CoV-2: the T cell perspective. Front. Immunol., 2023, vol. 14, 1107803. doi: 10.3389/fimmu.2023.1107803.
- Barros-Martins J., Hammerschmidt S.I, Morillas R.G., Cossmann A., Hetzel L., Odak I., Köhler M., Stankov M.V., Ritter C., Friedrichsen M., Ravens I., Schimrock A., Ristenpart J., Janssen A., Willenzon S., Bernhardt G., Lichtinghagen R., Bošnjak B., Behrens G.M.N., Förster R. Omicron infection-associated Tand B cell immunity in antigen-naive and tripleCOVID-19vaccinated individuals. Front. Immunol., 2023, vol. 14, 1166589. doi: 10.3389/fimmu.2023.1166589
- Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., Cheng B., Abu Raddad L.J., Buckeridge D.L., Van Kerkhove M.D., Piechotta V., Higdon M.M., Wilder-Smith A., Bergeri I., Feikin D.R., Arora R.K., Patel M.K., Subissi L. Protective effectiveness of previous SARS-Cov-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis., 2023, vol. 23, pp. 556–567.
- Gao Y., Cai C., Grifoni A., Muller T.R., Niessl J., Olofsson A., Humbert M., Hansson L., Österborg A., Bergman P., Chen P., Olsson A., Sandberg J.K., Weiskopf D., Price D.A., Ljunggren H.G., Karlsson A.C., Sette A., Aleman S., Buggert M. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med., 2022, vol. 28, no. 3, pp. 472–476.
- Jacobsen H., Jimenez V.C., Sitaras I., Bar-Zeev N., Cicin-Sain L., Higdon M.M., Deloria-Knoll M. (2022) Postvaccination T cell immunity to omicron. Front. Immunol., 2022, vol. 13, 944713. doi: 10.3389/fimmu.2022.944713.
- Keeton R., Tincho M.B., Ngomti A., Baguma R., Benede N., Suzuki A., Khan K., Cele S., Bernstein M., Karim F., Madzorera S.V., Moyo-Gwete T., Mennen M., Skelem S., Adriaanse M., Mutithu D., Aremu O., Stek C., du Bruyn E., Van Der Mescht M.A., de Beer Z., de Villiers T.R., Bodenstein A., van den Berg G., Mendes A., Strydom A., Venter M., Giandhari J., Naidoo Y., Pillay S., Tegally H., Grifoni A., Weiskopf D., Sette A., Wilkinson R.J., de Oliveira T., Bekker L.G., Gray G., Ueckermann V., Rossouw T., Boswell M.T., Bhiman J.N., Moore P.L., Sigal A., Ntusi NAB, Burgers W.A., Riou C. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature, 2022, vol. 603, no. 7901, pp. 488–492. doi: 10.1038/s41586–022-04460–3
- Lin J., Law R., Korosec C.S., Zhou C., Koh W.H., Ghaemi M.S., Samaan P., Ooi H.K., Matveev V., Yue F., Gingras A.C., Estacio A., Buchholz M., Cheatley P.L., Mohammadi A., Kaul R., Pavinski K., Mubareka S., McGeer A.J., Leis J.A., Heffernan J.M., Ostrowski M. Longitudinal assessment of SARS-CoV-2-specific T cell cytokine-producing responses for 1 year reveals persistence of multicytokine proliferative responses, with greater immunity associated with disease severity. J. Virol., 2022,vol. 96, no. 13, e0050922. doi: 10.1128/jvi.00509–22
- Naranbhai V., Nathan A., Kaseke C., Berrios C., Khatri A., Choi S., Getz M.A., Tano-Menka R., Ofoman O., Gayton A., Senjobe F., Zhao Z., St Denis K.J., Lam E.C., Carrington M., Garcia-Beltran W.F., Balazs A.B., Walker B.D., Iafrate A.J., Gaiha G.D. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell, 2022, vol. 185, no. 6, pp. 10⁴1–10⁵1. doi: 10.1016/j.cell.2022.01.029
Supplementary files
